Risk assessment of potentially genotoxic impurities within the framework of quality by design

Organic Process Research and Development

Volumn 14, Issue 4, 2010, Pages 1032-1036

  Looker, Adam R ^a   Ryan, Michael P ^a   Neubert Langille, Bobbianna J ^a   Naji, Redouan ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGN SPACES; DETECTION METHODS; GENOTOXIC IMPURITIES; MULTI VARIATE ANALYSIS; POTENTIAL IMPACTS; QUALITY BY DESIGNS; TOXICOLOGICAL TESTING;

CHEMICAL ANALYSIS; DESIGN; IMPURITIES; MULTIVARIANT ANALYSIS;

RISK ASSESSMENT;

EID: 77955347744     PISSN: 10836160     EISSN: 1520586X     Source Type: Journal    
DOI: 10.1021/op900338g     Document Type: Article

References (22)

1. Sobol, E.; Engel, M. E.; Rubitski, E.; Ku, W. W.; Aubrecht, J.; Schiestl, R. H. Mutat. Res. 2007, 633, 80
2. Leakakos, T.; Shank, R. C. Toxicol. Appl. Pharmacol. 1994, 126, 295
3. Muller, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; Antonis, D. D.; Beels, C.; DeGeorge, J.; De Knaep, A. G.; Fagerland, J. A.; Ellison, D.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.; Humfrey, C. D.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.; Ness, D. K.; O'Donovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L. Regul. Toxicol. Pharmacol. 2006, 44, 198
4. Guideline on the Limits of Genotoxic Impurities; EMEA Committee for Medicinal Products for Human Use, CPMP/SWP/5199: London, England, 2006.
5. Subpart B: Food Additive Safety, Section 170.39: Threshold of Regulation for Substances Used in Food-Contact Articles, Revised April 1, 2007. Code of Federal Regulations; Title 21, Food and Drugs; Office of the Federal Register, National Archives and Records Service, General Services Administration: Washington, DC, 2007; Chapter 1, Vol. 3.
6. Jacobsen-Kram, D.; McGovern, T. Adv. Drug Delivery Rev. 2007, 59, 38
7. Guidance for Industry, Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches, Draft; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Rockville, MD, 2008.
8. Richard, A. M. Mutat. Res. 1998, 400, 493
9. Wang, S.; Milne, G. W. Chem. Res. Toxicol. 1993, 6, 748
10. ICH Q8. Pharmaceutical Development. In International Conference on Harmonisation, Harmonised Tripartite Guideline; ICH Expert Working Group: Geneva, Switzerland, 2006.). (b)
11. ICH Q9. Quality Risk Management. In International Conference on Harmonisation, Harmonised Tripartite Guideline; ICH Expert Working Group: Geneva, Switzerland, 2006.
12. The approach described in this paper is likely similar to others industry wide. In designing this methodology, focus was directed at generating strong process understanding through the use of QbD whereby robust control points can be identified, thus ensuring patient safety.
13. ICH Q3A(R2). Impurities in New Drug Substances. In International Conference on Harmonisation, Harmonised Tripartite Guideline; ICH Expert Working Group: Geneva, Switzerland, 2006.
14. The following are definitions for observed and potential impurities. Observed impurity: impurity detected in isolated batches of starting material, intermediate, or API. Potential impurity: impurity seen during process, but not detected in starting material, intermediate, or API
15. Alternatively, one could perform the appropriate genotoxicity assays on these higher-risk PGIs prior to conducting further studies. If negative in these assays, no further work would be required. If positive, however, agencies would likely require their specification in the API. Under our approach, if the PGI is ultimately deemed noncritical, specification in the API would not be necessary, thus avoiding longer-term low-level detection requirements during commercial production.
16. For discussions on the mechanistic pathway of nitroaromatic hydrogenation chemistry, please see
17. Augustine, R. L. Heterogeneous Catalysis for the Synthetic Organic Chemist; Marcel Dekker, Inc., 1996; p 473.
18. The design spaces for the crystallization and isolation procedures were evaluated separately.
19. For information on multiple regression analysis, please see
20. Chatterjee, S.; Hadi, A. S. Regression Analysis by Example; John Wiley & Sons, Inc.: Hoboken, NJ, 2006.
21. Keith, T. Z. Multiple Regression and Beyond; Allyn & Bacon: Boston, 2005.
22. Sen, A.; Srivastava, M. Regression Analysis: Theory, Methods, and Applications; Springer-Verlag New York Inc.: New York, 1990.